Remdesivir

SKU: orb1299527

Description

Remdesivir (GS-5734) is a broad-spectrum antiviral nucleoside analog prodrug that inhibits viral RNA-dependent RNA polymerase. It has demonstrated in vitro and in vivo activity against Ebola, SARS, MERS, and SARS-CoV-2 viruses, supporting its research use for coronavirus and filovirus studies.

Research Area

Cell Biology, Infectious Disease & Virology, Molecular Biology, Pharmacology & Drug Discovery

Key Properties

• CAS Number: 1809249-37-3
• MW: 602.58
• Purity: >99.99% (May vary between batches)
• Formula: C₂₇H₃₅N₆O₈P
• SMILES: C(#N)[C@]1(O[C@H](COP(OC2=CC=CC=C2)(N[C@H](C(OCC(CC)CC)=O)C)=O)[C@@H](O)[C@H]1O)C=3N4C(=CC3)C(N)=NC=N4
• Target: DNA/RNA Synthesis,SARS-CoV
• Solubility: 10% DMSO+40% PEG300+5% Tween 80+45% Saline:12.5 mg/mL (20.74 mM);DMSO:240 mg/mL (398.29 mM)

Bioactivity

• Target IC50:
  Caco-2 cells:0.76 μM|MERS-CoV:74 nM (EC50)|SARS-CoV-2:0.77 μM (EC50)|HeLa cells:0.1 μM (EC50)|HEp-2 cells:0.11 μM|SARS-CoV:74 nM (EC50)|Vero cells C1008:0.62 μM (EC50)|MHV:0.03 µM (EC50)
  Read more...
• In Vivo:
  METHODS: To assay antiviral activity in vivo, Remdesivir (25 mg/kg, 12% sulfobutylether-β-cyclodextrin sodium salt in water (with HCl/NaOH) at pH 5.0) was injected subcutaneously into MERS-CoV-infected Ces1c-/- hDPP4 mice twice daily. RESULTS: Prophylactic Remdesivir reduced MERS-CoV replication and disease. METHODS: To assay antiviral activity in vivo, Remdesivir (25 mg/kg once daily, administered three times) and Loratadine (10 mg/kg once daily, administered four times) were administered intraperitoneally to 501Y.V2 SARS-CoV-2 infected BALB/c mice. RESULTS: The combination of Remdesivir and the antihistamine Loratadine reduced SARS-CoV-2 replication and inflammation and protected against lung injury.
  Read more...
• In Vitro:
  METHODS: Mouse hepatitis virus (MHV)-infected DBT cells were incubated with Remdesivir (0.01-1 µM) for 24 h, and the supernatant was analyzed for viral titer by plaque assay. RESULTS: Remdesivir effectively inhibited MHV with an EC50 of 0.03 µM. METHODS: 2019-nCoV-infected Vero E6 cells were treated with Remdesivir (0-400 µM) for 48 h. Viral yield in cell supernatants was detected using qRT-PCR. RESULTS: Remdesivir effectively blocked viral infection at low micromolar concentrations and showed high SI (EC50 = 0.77 μM; CC50 > 100 μM; SI > 129.87).
  Read more...

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

2019-nCoV, antiviral, COVID-19, DNASynthesis, DNA Synthesis, DNA/RNA Synthesis, infection, inhibit, Inhibitor, MERS-CoV, GS5734, GS-5734, GS 5734, SARSCoV, SARS coronavirus, SARS-CoV, RNA Synthesis, RNASynthesis, Remdesivir

Compound Identifiers

PubChem CID

56832851